McDonald's (MCD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
MCD leans on digital deals and loyalty rewards to lift traffic and satisfaction amid tough comps and consumer headwinds.
McDonald's has been an investors favorite for decades, providing superior returns. Recent financials do not match this greatness, with sales and profits declining YoY. I argue that this is likely a temporary effect and McDonald's is a long-term Buy at a fair valuation and a 2.5% dividend yield.
McDonald's (MCD) reached $291.55 at the closing of the latest trading day, reflecting a +2.07% change compared to its last close.
While a third of Dow stocks boast double-digit gains for 2025, McDonald's Corp (NYSE:MCD) has been on the sidelines, treading water above its year-to-date breakeven level.
McDonald's Corp. (NYSE: MCD) stock has declined by about 8% over the past month, as analysts are not particularly impressed with the company's latest earnings report. Same-store sales, a critical metric for companies like McDonald's, fell by more than 2%.
McDonald's (MCD) reached $296.29 at the closing of the latest trading day, reflecting a -1.86% change compared to its last close.
MCD is advancing its value platform, tech innovation and category expansion amid ongoing macroeconomic headwinds.
McDonald's Corp (NYSE:MCD, ETR:MDO) presents a compelling buying opportunity on recent share weakness, analysts at Jefferies believe, citing near-term same-store sales acceleration and medium-term unit growth. The analysts maintained their price target of $360 on ‘Buy'-rated McDonald's, implying upside of 19% from Thursday's closing price of about $303.
Zacks.com users have recently been watching McDonald's (MCD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The 'Fast Money' traders taste test McDonald's McCrispy chicken strips.
McDonald's stock was heading for its longest losing streak in 12 years after Redburn Atlantic recommended investors sell due to concerns over the impact of weight-loss drugs and relatively high prices.